MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it is initiating
the development of an Artificial Intelligence Engine with leading
dermatologists and its technology partner, Blanc Labs, that will work in
conjunction with its existing DermSecureTM screening
platform. MedX has an opportunity to leverage Artificial Intelligence to
create a unique assessment support tool allowing Dermatologists to more
accurately assess suspicious moles and lesions from remote locations.
MedX’s advanced SIAscopy imaging technology lends itself to AI because
of the specialized image capture above and below the skin’s surface.
“SIAscopy is the only imaging technology that provides a dermascopic
image along with four additional proprietary pathophysiology views 2 mm
below the skin’s surface, produced in a consistent format, and we
believe this large amount of data will increase the accuracy of our AI
engine” said Scott Spearn, MedX’s President and CEO.
MedX has been working closely with its Scientific Medical Advisory Board
(“SMAB”) to launch an AI strategy that will complement DermSecureTM
and current assessment protocols. Dr. Trevor Champagne commented, “MedX
has got the AI questions right. The question that AI needs to address is
not what is a melanoma, but what is not a melanoma? What do we need to
concentrate on with our biopsies and diagnosis? What can we safely
exclude from this pool of potentially dangerous lesions? MedX’s thinking
around AI is extremely important and I look forward to collaborating
with them on this important advancement in the field of Dermatology.”
Dr. Joe Walls, also on MedX’s SMAB further noted “I wrote my thesis on
SIAscopy and have been deeply involved in analyzing SIAscopic images in
my professional practice. I think the advanced standardized images that
SIAscopy produces will deeply enhance the AI process. AI only works when
you have quality input and SIAscopy produces unique images not found in
other imaging technologies,” noted Dr. Walls.
MedX looks forward to taking the next step with Blanc Labs on this
important strategic initiative. “Adding AI features to the DermSecureTM
platform is a natural evolution for this advanced medical imaging
solution,” noted Dariush Zomorrodi, Blanc Lab’s Chief Innovation
Officer, who has been collaborating with MedX on the development of
DermSecureTM. “We will apply Machine Learning technology to a
collection of images and diagnostic data. With the increase of data
size, over time, the Deep Learning algorithm will enable the platform to
deliver a highly accurate assessment tool to Dermatologists, and we are
very excited to continue innovating with MedX, pushing the boundaries,
and making an impact on the early detection of skin cancer.”
MedX, headquartered in Mississauga, Ontario, is a leading medical device
and software company focused on skin cancer with its DermSecure™
telemedicine platform, utilizing its SIAscopy technology. SIAscopy is
also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which
MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™,
SIMSYS™, and MoleMate™ include hand-held devices that use patented
technology utilizing light and its remittance to view up to 2 mm beneath
suspicious moles and lesions in a pain free, non-invasive manner, with
its software then creating real-time images for physicians and
dermatologists to evaluate all types of moles or lesions within seconds.
These products are Health Canada, FDA (US), ARTG and CE cleared for use
in Canada, the US, Australia, New Zealand, the European Union and
Turkey. MedX also designs, manufactures and distributes quality
photobiomodulation therapeutic and dental lasers to provide drug-free
and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which
reflect the Company’s current expectations regarding future events. The
forward-looking statements involve risks and uncertainties.
Scott Spearn, President and CEOMedX Health Corp905-670-4428
Media RelationsDeborah Thompson[email protected]416-918-9551